Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Optimizing Chemotherapy in Non-Small Cell Lung Cancer

Optimizing Chemotherapy in Non-Small Cell Lung Cancer Am J Cancer 2006; 5 (4): 211-212 COMMENTARY 1175-6357/06/0004-0211/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. Optimizing Chemotherapy in Non-Small Cell Lung Cancer Rafael Rosell Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain The readers will enjoy the exhaustive review on non-platinum- genes between platinum and antimicrotubule drugs has been fully [1] [9] based chemotherapy in NSCLC by Tummala and Edelman, as reported. The clinical interpretation is that patients whose tu- well as the extensive data on non-taxane-based chemotherapy also mors have low levels of DNA repair genes, such as BRCA1 or [2] in NSCLC, by Bergqvist et al., both published in this issue of the ERCC1, could have a better response and survival with single Journal. Both articles are welcome since they contain comprehen- agents such as cisplatin or cisplatin plus gemcitabine, the latter a sive information on all types of clinical trials that have been neutral drug that is not influenced by BRCA1, while patients published in the field of NSCLC in recent years; hundreds of whose tumors display high levels of DNA repair genes could be studies showing the clinical outcomes of different platinum and more resistant to cisplatin while being http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png American Journal of Cancer Springer Journals

Optimizing Chemotherapy in Non-Small Cell Lung Cancer

American Journal of Cancer , Volume 5 (4) – Aug 9, 2012

Loading next page...
 
/lp/springer-journals/optimizing-chemotherapy-in-non-small-cell-lung-cancer-az0iIFIISV
Publisher
Springer Journals
Copyright
Copyright © 2006 by Adis Data Information BV
Subject
Pharmacy; Pharmacy
ISSN
1175-6357
DOI
10.2165/00024669-200605040-00001
Publisher site
See Article on Publisher Site

Abstract

Am J Cancer 2006; 5 (4): 211-212 COMMENTARY 1175-6357/06/0004-0211/$39.95/0 © 2006 Adis Data Information BV. All rights reserved. Optimizing Chemotherapy in Non-Small Cell Lung Cancer Rafael Rosell Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain The readers will enjoy the exhaustive review on non-platinum- genes between platinum and antimicrotubule drugs has been fully [1] [9] based chemotherapy in NSCLC by Tummala and Edelman, as reported. The clinical interpretation is that patients whose tu- well as the extensive data on non-taxane-based chemotherapy also mors have low levels of DNA repair genes, such as BRCA1 or [2] in NSCLC, by Bergqvist et al., both published in this issue of the ERCC1, could have a better response and survival with single Journal. Both articles are welcome since they contain comprehen- agents such as cisplatin or cisplatin plus gemcitabine, the latter a sive information on all types of clinical trials that have been neutral drug that is not influenced by BRCA1, while patients published in the field of NSCLC in recent years; hundreds of whose tumors display high levels of DNA repair genes could be studies showing the clinical outcomes of different platinum and more resistant to cisplatin while being

Journal

American Journal of CancerSpringer Journals

Published: Aug 9, 2012

References